ivosidenib (Tibsovo)
Jump to navigation
Jump to search
Indications
- relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation
Dosage
- 500 mg QD
Adverse effects
- low frequency of serious adverse effects
Laboratory
Mechanism of action
- inhibits mutant IDH1
- transfusion independence, durable remissions
More general terms
Additional terms
References
- ↑ Ingram I. Ivosidenib Induces Deep Remissions in IDH1-Mutant AML On strength of phase I data, drug appears headed for FDA approval. MedPage Today. June 03, 2018 https://www.medpagetoday.com/meetingcoverage/asco/73242
DiNardo CD, Stein EM, de Botton S et al Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. Jun 2, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29860938 https://www.nejm.org/doi/full/10.1056/NEJMoa1716984
Pollyea DA, et al Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study. American Society of Clinical Oncology (ASCO) 2018; Abstract 7000 - ↑ HIGHLIGHTS OF PRESCRIBING INFO TIBSOVO (ivosidenib tablets), for oral use https://www.tibsovopro.com/pdf/prescribinginformation.pdf